Olesiński Tomasz, Malinowska Małgorzata, Zwierko Maria, Pogoda Katarzyna, Rutkowski Andrzej, Szpakowski Marek, Saramak Piotr, Nasierowska-Guttmejer Anna
Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland -
Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
Minerva Chir. 2018 Jun;73(3):261-268. doi: 10.23736/S0026-4733.18.07529-6. Epub 2018 Feb 1.
The aim of this study was to verify if positive results yielded with conventional cytology and immunocytochemical analysis of peritoneal washes correlate with established prognostic factors and overall survival (OS) in gastric cancer patients.
The study included the data of 271 gastrectomized patients. Peritoneal washes of 131 (48.3%) patients were examined by means of conventional cytology, and material from 140 (51.7%) subjects treated surgically after this date was subjected to immunocytochemical analysis.
Free cancer cells (FCCs) were detected significantly less often in patients from conventional cytology group than in those from immunocytochemistry group (4.6% vs. 12.1%). Positive result of immunocytochemical analysis was significantly more often associated with presence of pT3/4 tumor (94.1% vs. 60.2%), lymph node ratio ≥0.2 (82.4% vs. 43.1%) and involvement of blood vessels (64.7% vs. 28.5%). Median OS in patients with immunocytochemical evidence of FCCs in peritoneal washes was significantly shorter than in those without (11 vs. 45 months). Moreover, the two groups differed significantly in terms of 5- (0% vs. 43.1%) and 10-year OS rates (0.0% vs. 29.3%).
In contrast to conventional cytology, immunocytochemically documented presence of FCCs in peritoneal washes correlates with established prognostic factors and OS in gastric cancer patients.
本研究的目的是验证胃癌患者腹膜灌洗的传统细胞学和免疫细胞化学分析所产生的阳性结果是否与既定的预后因素和总生存期(OS)相关。
该研究纳入了271例接受胃切除术患者的数据。对131例(48.3%)患者的腹膜灌洗进行了传统细胞学检查,在此之后接受手术治疗的140例(51.7%)患者的材料进行了免疫细胞化学分析。
传统细胞学组患者中检测到游离癌细胞(FCCs)的频率明显低于免疫细胞化学组(4.6%对12.1%)。免疫细胞化学分析的阳性结果更常与pT3/4期肿瘤的存在(94.1%对60.2%)、淋巴结比率≥0.2(82.4%对43.1%)和血管受累(64.7%对28.5%)相关。腹膜灌洗中有FCCs免疫细胞化学证据的患者的中位总生存期明显短于无此证据的患者(11个月对45个月)。此外,两组在5年(0%对43.1%)和10年总生存率方面也有显著差异(0.0%对29.3%)。
与传统细胞学不同,免疫细胞化学记录的腹膜灌洗中FCCs的存在与胃癌患者既定的预后因素和总生存期相关。